These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 16855128)

  • 1. Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample.
    Sullivan PW; Ghushchyan V
    Med Decis Making; 2006; 26(4):401-9. PubMed ID: 16855128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preference-Based EQ-5D index scores for chronic conditions in the United States.
    Sullivan PW; Ghushchyan V
    Med Decis Making; 2006; 26(4):410-20. PubMed ID: 16855129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A; Green C; Telford C; Zajicek J; Wright D
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catalogue of EQ-5D scores for the United Kingdom.
    Sullivan PW; Slejko JF; Sculpher MJ; Ghushchyan V
    Med Decis Making; 2011; 31(6):800-4. PubMed ID: 21422468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting EuroQoL EQ-5D preference scores from the SF-12 Health Survey in a nationally representative sample.
    Lawrence WF; Fleishman JA
    Med Decis Making; 2004; 24(2):160-9. PubMed ID: 15090102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probabilistic mapping of the health status measure SF-12 onto the health utility measure EQ-5D using the US-population-based scoring models.
    Le QA
    Qual Life Res; 2014 Mar; 23(2):459-66. PubMed ID: 24026631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
    Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting the EuroQol Group's EQ-5D index from CDC's "Healthy Days" in a US sample.
    Jia H; Zack MM; Moriarty DG; Fryback DG
    Med Decis Making; 2011; 31(1):174-85. PubMed ID: 20375418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EQ-5D Scores for Diabetes-Related Comorbidities.
    Sullivan PW; Ghushchyan VH
    Value Health; 2016 Dec; 19(8):1002-1008. PubMed ID: 27987626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population.
    Petrou S; Hockley C
    Health Econ; 2005 Nov; 14(11):1169-89. PubMed ID: 15942981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scale characteristics and mapping accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in patients with rheumatoid arthritis.
    Wolfe F; Michaud K; Wallenstein G
    J Rheumatol; 2010 Aug; 37(8):1615-25. PubMed ID: 20551106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the EQ-5D-3L Preference Index from the SF-12 Health Survey in a National US Sample: A Finite Mixture Approach.
    Coca Perraillon M; Shih YC; Thisted RA
    Med Decis Making; 2015 Oct; 35(7):888-901. PubMed ID: 25840902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deriving a mapping algorithm for converting SF-36 scores to EQ-5D utility score in a Korean population.
    Kim SH; Kim SO; Lee SI; Jo MW
    Health Qual Life Outcomes; 2014 Sep; 12():145. PubMed ID: 25248494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.
    Yang Q; Yu XX; Zhang W; Li H
    Health Qual Life Outcomes; 2019 Oct; 17(1):153. PubMed ID: 31615531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating EuroQol EQ-5D scores from Population Healthy Days data.
    Jia H; Lubetkin EI
    Med Decis Making; 2008; 28(4):491-9. PubMed ID: 18556640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping the Positive and Negative Syndrome Scale scores to EQ-5D-5L and SF-6D utility scores in patients with schizophrenia.
    Abdin E; Chong SA; Seow E; Verma S; Tan KB; Subramaniam M
    Qual Life Res; 2019 Jan; 28(1):177-186. PubMed ID: 30382480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probabilistic mapping of descriptive health status responses onto health state utilities using Bayesian networks: an empirical analysis converting SF-12 into EQ-5D utility index in a national US sample.
    Le QA; Doctor JN
    Med Care; 2011 May; 49(5):451-60. PubMed ID: 21422961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of contemporaneous EQ-5D and SF-6D responses using scoring algorithms derived from similar valuation exercises.
    Whitehurst DG; Norman R; Brazier JE; Viney R
    Value Health; 2014 Jul; 17(5):570-7. PubMed ID: 25128050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.
    Liu T; Li S; Wang M; Sun Q; Chen G
    Patient; 2020 Oct; 13(5):537-555. PubMed ID: 32382953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.
    Teckle P; McTaggart-Cowan H; Van der Hoek K; Chia S; Melosky B; Gelmon K; Peacock S
    Health Qual Life Outcomes; 2013 Dec; 11():203. PubMed ID: 24289488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.